The use of epoetin beta in cardiac arrest victims: the impact on survival and neurological outcome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-006453-27-SI

Enrollment

200

Registered

2007-01-23

Start date

2007-02-01

Completion date

Unknown

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The aim of our prospective, randomized, multicentered and controlled research is to determine the impact of erythropoietin on survival and neurological outcome of cardiac arrest victims. On the basis of previous research we expect that giving erythropoietin early in the course of cardiopulmonary resuscitation would decrease the ischaemic and reperfusion damage to the brain and heart after a period of cardiac arrest and thus it would improve neurological outcome of these patients. MedDRA version

Interventions

Trade Name: NeoRecormon Product Name: NeoRecormon Product Code: R02053859 Pharmaceutical Form: Solution for injection INN or Proposed INN: epoetin beta CAS Number: 122312543 Concentration unit: IU int

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study includes cardiac arrest patients of 18 years old and more and with cardiac arrest of any aethyiology. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Excluding criteria are terminal malignant diseases and conditions incompatible with life.

Design outcomes

Primary

Measure	Time frame
Main Objective: The aim of our prospective, randomized, multicenter and controlled research is to determine the impact of erythropoietin on survival and neurological outcome of cardiac arrest victims. On the basis of previous research we expect that giving erythropoietin early in the course of cardiopulmonary resuscitation would decrease the ischaemic and reperfusion damage to the brain and heart after a period of cardiac arrest and thus it would improve neurological outcome of these patients.;Secondary Objective: Secondary objectives of the study are the impact of erythropoietin on return of spontaneous circulation in cardiac arrest victims, survival to hospital admission, discharge from hospital, and 6-month survival after succesfull cardiopulmonary resuscitation of the cardiac arrest victims;Primary end point(s): To determine the impact of erythropoietin on survival and neurological outcome of cardiac arrest victims.	—

Measure

Time frame

Main Objective: The aim of our prospective, randomized, multicenter and controlled research is to determine the impact of erythropoietin on survival and neurological outcome of cardiac arrest victims. On the basis of previous research we expect that giving erythropoietin early in the course of cardiopulmonary resuscitation would decrease the ischaemic and reperfusion damage to the brain and heart after a period of cardiac arrest and thus it would improve neurological outcome of these patients.;Secondary Objective: Secondary objectives of the study are the impact of erythropoietin on return of spontaneous circulation in cardiac arrest victims, survival to hospital admission, discharge from hospital, and 6-month survival after succesfull cardiopulmonary resuscitation of the cardiac arrest victims;Primary end point(s): To determine the impact of erythropoietin on survival and neurological outcome of cardiac arrest victims.

—

Countries

Slovenia

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026